Pharmafile Logo
Pharmafocus logo
Advanced Search

epilepsy

Showing 15 posts of 52 posts found.

pfizerbrussels

Pfizer fined for epilepsy drug price increase by UK antitrust regulator

April 15, 2016
Medical Communications CMA, Flynn Pharma, Pfizer, antitrust, competition and markets authority, epilepsy, fine, flynn

Pfizer has been fined for unfairly increasing the price of epilepsy drug Epanutin (phenytoin sodium) by the UK Competition and …

News
ucb_logo

New epilepsy drug launches in UK

February 29, 2016
Medical Communications, Research and Development, Sales and Marketing Briviact, UCB Pharma, epilepsy

UCB Pharma’s Briviact (brivaracetam) has been authorised as an add-on treatment for partial onset seizures (POS), with or without secondary …

News

UCB plots new Vimpat submissions after positive monotherapy results

October 8, 2015
Research and Development EMA, European Medicines Agency, UCB, carbamazepine, epilepsy, lacosamide, phase III, vimpat

A Phase III non-inferiority study comparing UCB’s Vimpat with carbamazepine suggests the two drugs can be used as monotherapy treatments.  …

News
Sun Pharma logo

FDA withdraws approval for Sun Pharma’s epilepsy drug

September 29, 2015
Manufacturing and Production Elepsia, FDA, Sun Pharma, epilepsy, levetiracetam, manufacturing, productions, seizures

Manufacturing problems at Sun Pharma’s production site has led the FDA to revoke the company’s approval for Elepsia XR for …

News
lyrica

High Court rules against Pfizer in Lyrica patent case

September 10, 2015
Medical Communications, Sales and Marketing Actavis, Lyrica, Pfizer, anxiety, epilepsy, generics, neuropathic pain, pregabalin

The High Court of England and Wales today ruled against Pfizer in the patent battle with Actavis on Pfizer’s blockbuster …

News

Pfizer and Flynn rapped for overcharging on anti-epilepsy drug

August 6, 2015
Manufacturing and Production, Sales and Marketing CMA, Drug pricing, Flynn Pharma, Pfizer, competitions markets authority, epilepsy, generics, phenytoin, pricing

Pharma firms Pfizer and Flynn Pharma have been accused by the UK’s competition watchdog of charging ‘excessive and unfair’ prices …

News

UCB sponsors ‘Hack Epilepsy’ digital event

March 12, 2015
Medical Communications, Sales and Marketing Keppra, UCB, epilepsy, hack, lacosamide, levetiracetam, vimpat

Belgian biopharma firm UCB says it will be sponsoring a ‘Hack Epilepsy’ event this year to help support patient needs …

News
UCB image

UCB epilepsy drug reaches regulatory bodies

January 21, 2015
Research and Development, Sales and Marketing EMA, FDA, UCB, brivaracetam, epilepsy

UCB has established regulatory milestones for its investigational antiepileptic drug brivaracetam in Europe and the US. The Food and Drug …

News
Eisai image

Eisai: Fycompa decision ‘deeply regrettable’

November 11, 2014
Research and Development, Sales and Marketing Eisai, Fycompa, Germany, epilepsy, gba, perampanel

Eisai has lashed out at a major German health assessment body, calling its stance on first-in-class epilepsy treatment Fycompa ‘deeply …

News
Eisai image

SMC first to give Fycompa thumbs-up

December 12, 2012
Sales and Marketing Eisai, Fycompa, SMC, Scotland, epilepsy

The Scottish Medicines Consortium (SMC) has approved Eisai’s first-in-class epilepsy drug Fycompa for use in the NHS in Scotland – …

News
Eisai image

Eisai launches epilepsy drug in UK

September 14, 2012
Sales and Marketing Eisai, UK, epilepsy

Eisai has launched its first-in-class epilepsy drug Fycompa in the UK, prior to a roll-out in EU member states including …

News

Eisai to enter Russia with epilepsy launch

June 27, 2012
Sales and Marketing Eisai, Russia, Zonegran, emerging markets, epilepsy

Eisai is to enter the Russian market for the first time with the launch of epilepsy drug Zonegran. Entry into the …

News

Recommendations for two Eisai epilepsy drugs

May 28, 2012
Sales and Marketing CHMP, Eisai, Zonegra, epilepsy

European regulators are likely to approve two of Eisai’s epilepsy drugs after advisers recommended both of them.First-in-class Fycompa (perampanel) has …

News

UCB signs new epilepsy research pact with Imperial

May 21, 2012
Research and Development, Sales and Marketing R&D, Scotland, UCB, epilepsy

UCB has signed a two-year research deal with Imperial College London to find disease-modifying targets in epilepsy. The firm has …

News
UCB image

UCB releases ‘Epilepsy In Our Time’ video diaries

February 17, 2012
Medical Communications UCB, epilepsy

UCB has released Epilepsy In Our Time, a video diary that explores life with epilepsy from the perspective of those …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026